<DOC>
	<DOCNO>NCT00246571</DOCNO>
	<brief_summary>The purpose study compare progression free survival SU011248 [ sutent ( sunitinib malate ) ] versus standard care therapy patient previously treat , advance , triple receptor negative ( ER , PR , HER2 ) locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Recurrent metastatic breast cancer Estrogen receptor ( ER ) , progestin receptor ( PR ) HER2/neu receptor ( HER2 ) negative status Prior treatment anthracycline taxane adjuvant advance disease set Relapse follow adjuvant chemotherapy within 6 month last treatment and/or receive one two chemotherapy regimen advance disease More two chemotherapy regimen advance disease Uncontrolled/symptomatic spread cancer brain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>